{"id":"W4321436832","doi":"10.1200/jco.22.01989","title":"Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":643,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hôpital Charles-Le Moyne","funders":"Chugai Pharmaceutical; EMD Serono; Genentech; Ipsen; Eli Lilly and Company; Ono Pharmaceutical; Astellas Pharma; Eisai; Regeneron Pharmaceuticals; Natera; Grifols; Y-mAbs Therapeutics; Shionogi; Actuate Therapeutics; Daiichi Sankyo Europe; Gilead Sciences; Calithera Biosciences; Pfizer; Incyte; Mirati Therapeutics; Les Laboratories Pierre Fabre; Helsinn; Merck KGaA; Sanofi; GlaxoSmithKline; Helsinn Therapeutics; Amgen; Celgene; AstraZeneca; Samsung; Bristol-Myers Squibb","keywords":"Pemetrexed; Medicine; Pembrolizumab; Carboplatin; Internal medicine; Lung cancer; Oncology; Clinical endpoint; Hazard ratio; Phases of clinical research; Clinical trial; Surgery; Cisplatin; Chemotherapy; Cancer; Confidence interval; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003434363,0.0001894673,0.001529388,0.0001805908,0.00007178127,0.0000201044,0.0002552205,0.0002755033,0.0002743461],"category_scores_gemma":[0.001148173,0.0001114135,0.0003819261,0.0003992664,0.0001741852,0.00006509524,0.00009755846,0.001113902,0.00001003591],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002595377,"about_ca_system_score_gemma":0.001592903,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001176794,"about_ca_topic_score_gemma":0.002041072,"domain_scores_codex":[0.9964613,0.0004909988,0.002113636,0.0002573949,0.0003759918,0.0003006867],"domain_scores_gemma":[0.9936728,0.004652299,0.001060737,0.0002658516,0.0001448015,0.0002034516],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.03289663,0.002327397,0.8705879,0.0000256929,0.0008116397,0.001191558,0.001976838,0.00002247623,0.0004068061,0.000001222657,0.007744926,0.08200692],"study_design_scores_gemma":[0.1009863,0.008653657,0.880575,0.00009088382,0.0005544513,0.00002892433,0.002725719,0.0008460642,0.00003101294,0.00002211147,0.005364005,0.0001218753],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9870902,0.001304774,0.00001439488,0.008936661,0.001498601,0.0006797449,0.0000210592,0.00001548937,0.000439105],"genre_scores_gemma":[0.9944464,0.002043131,0.0001656435,0.002075675,0.0007565906,0.00001904694,0.000003979692,0.0000244221,0.0004651235],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.08188504,"threshold_uncertainty_score":0.4839413,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1147099508522471,"score_gpt":0.4737687742129537,"score_spread":0.3590588233607066,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}